Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Mauna Kea Technologies S.A. is a pioneering company in the field of medical technology, specializing in the development and commercialization of endomicroscopy systems. Its primary purpose is to enhance the diagnostic capabilities of healthcare professionals by providing high-resolution, real-time imaging at the cellular level, which can be crucial for early and accurate disease detection. A notable feature of Mauna Kea Technologies is its flagship product, the Cellvizio platform, which is utilized across various medical fields such as gastrointestinal, urology, pulmonology, and ENT (ear, nose, and throat) applications. This technology aids doctors by streamlining the diagnostic process and potentially reducing the need for more invasive procedures. Based in France, Mauna Kea Technologies holds a significant position in the market due to its innovative approach to diagnostics, which aligns with the ongoing demand for improving patient outcomes and healthcare efficiency. As the medical industry continues to evolve with a focus on precision medicine, Mauna Kea Technologies plays a pivotal role in advancing diagnostic solutions worldwide.
The business is unprofitable at the operating level (-63.18% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 7.4%, steady but not accelerating.
ROIC dropped from -15.49% to -23.61%, capital efficiency is deteriorating. Negative free cash flow of -€4M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
€8M
▲ +7.4% YoY
Net Income (TTM)
€11M
▲ +203.5% YoY
Op. Margin
-63.18%
▲ +15.8pp YoY
ROIC
-23.61%
▼ -8.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€4M
▲ +40.5% YoY
Op. Cash Flow (TTM)
-€4M
▲ +41.8% YoY
Net Debt
€7M
Cash & Equiv.
€5M
3Y CAGR: +3.2%
Continue Research